Transcranial Photobiomodulation: Hope for Children with ASD Aged 2-6

Autism Spectrum Disorders (ASD) affect an increasing number of children worldwide, posing a challenge for both parents and specialists. The latest clinical research, published in a renowned scientific journal, brings hope – transcranial photobiomodulation (tPBM) may be a safe and effective method to support autism therapy in the youngest patients.

What is transcranial photobiomodulation?

Transcranial photobiomodulation is a non-invasive therapeutic method that uses light of a specific wavelength (most often in the red and near-infrared range) to stimulate biological processes in the brain. This technology, available in devices such as Lumaflex Essential Pro, penetrates the skull and acts on nerve cells, supporting their function.

How does photobiomodulation work?

The mechanism of tPBM is based on:

• Mitochondrial stimulation – increased ATP (cellular energy) production
• Improved blood flow in the brain
• Reduction of inflammation and oxidative stress
• Support for neuroplasticity – the brain's ability to form new neural connections

Groundbreaking clinical study – what did the results show?

A randomized controlled clinical trial conducted on children aged 2-6 with an ASD diagnosis yielded promising results. Researchers evaluated both the safety and efficacy of transcranial photobiomodulation therapy.

Key findings from the study:

1. Therapy safety
Transcranial photobiomodulation proved to be completely safe for young children. No serious adverse events were reported, making this method an attractive alternative to more invasive forms of therapy.

2. Improvement in clinical symptoms
Children undergoing tPBM therapy showed significant improvement in:

• Social and communication skills
• Reduction of stereotypical behaviors
• Improved eye contact
• Better cognitive functioning

3. Changes in brain electrophysiology
EEG (electroencephalography) studies showed positive changes in brain electrical activity, suggesting that photobiomodulation indeed affects the functioning of the nervous system at a physiological level.

Lumaflex Essential Pro – photobiomodulation technology at home

Devices like Lumaflex Essential Pro enable light therapy to be used at home, under specialist supervision. This solution is particularly valuable for parents of children with autism who are looking for:

• Non-invasive methods to support therapy
• Safe solutions backed by scientific research
• Convenience – the ability to conduct sessions in the comfort of home
• Complementary support for traditional forms of behavioral and speech therapy

Who is transcranial photobiomodulation for?

tPBM therapy may be considered as part of a comprehensive therapeutic program for children:

• Diagnosed with Autism Spectrum Disorders (ASD)
• Of preschool age (2-6 years), when the brain shows the greatest neuroplasticity
• Whose parents are seeking methods to support cognitive and social development
• Requiring non-invasive therapeutic support

Perspectives and future of therapy

The results of research on transcranial photobiomodulation in children with autism open new possibilities in ASD therapy. Although further research on larger patient groups is needed, current scientific data are extremely promising.

Photobiomodulation does not replace traditional forms of therapy, but can be a valuable complement to the therapeutic program, supporting the child's development at a neurobiological level.

Lumaflex Essential Pro Premium – Advanced Technology for tPBM Therapy

If you are considering transcranial photobiomodulation in the therapy of a child with autism, it is worth knowing the technical parameters of the Lumaflex Essential Pro Premium 2025 device – a professional class II medical device with FDA certification.

Key technical parameters:

• 6 therapeutic wavelengths: 630nm + 660nm + 810nm + 850nm + 904nm + 1064nm
• Output power: 68mW (35mW red light + 33mW infrared)
• Treatment time: Only 10 minutes daily
• Certifications: FDA (Class II) and CE

  Why is wavelength alone not enough in light therapy?

  When choosing a device for photobiomodulation (tPBM), many people look at the number of wavelengths. This is an important parameter, but not sufficient. For therapy to be effective, the device must also have adequate output power, penetration depth, emission stability, and medical certifications. Without these elements, even the most advanced wavelength spectrum may not produce the desired therapeutic effects.

  Lumaflex Essential Pro Premium – advanced light therapy

  The Lumaflex Essential Pro Premium device uses six wavelengths: 630 nm, 660 nm, 810 nm, 850 nm, 904 nm, and 1064 nm. Each penetrates tissues to a different depth and acts on various biological structures:

  • 630 nm – acts superficially, supports microcirculation and skin regeneration

  • 660 nm – stimulates nerve cells, increases ATP production

  • 810 nm – reaches deeper brain structures, supports neuroplasticity

  • 850 nm – enhances anti-inflammatory and neuroprotective effects

  • 904 nm – used pulsed, improves nerve conduction

  • 1064 nm – penetrates deepest, affects autonomic functions and biological rhythms

    The combination of these waves allows for multi-level therapeutic action – from the skin surface to brainstem structures. The device has FDA Class II and CE certifications, and its output power is 68 mW (35 mW red light + 33 mW infrared). The treatment time is just 10 minutes daily.

    
    

    Why does power matter?

    Wavelength determines penetration depth, but output power (measured in mW) affects the intensity of cellular stimulation, the time needed to achieve a therapeutic effect, and treatment safety. Devices with unknown or too low power may not achieve clinical effects, even if they have similar wavelengths.

     

   

The device uses precisely selected wavelengths that penetrate tissues at various depths, supporting regenerative processes and brain neuroplasticity. By using 6 different wavelengths, Essential Pro Premium provides comprehensive therapeutic action in line with the latest scientific research on photobiomodulation. The Lumaflex device is also available on the European market, including Poland

📘 Recommended reading: "Autism. I Understand" from Niebieska Fala

If you are looking for a valuable book that introduces the world of children on the autism spectrum in a simple and empathetic way — be sure to reach for "Autism. I Understand." This colorfully illustrated publication was created by members of the Niebieska Fala Association in cooperation with children and parents from Kindergarten No. 91 "Bajka" in Poznań.

Ideal for shared reading at home, kindergarten, or school. It helps discuss empathy, acceptance, and understanding — values worth cultivating from an early age.

By purchasing the book, you support activities for children and individuals on the autism spectrum. Find out more on the Niebieska Fala website. 

Summary

A randomized clinical trial confirms that transcranial photobiomodulation is a safe and effective method to support therapy for children with autism aged 2-6 years. Technology available in devices such as Lumaflex Essential Pro can help parents and therapists comprehensively support the development of the youngest patients with ASD.

Source: Study published in PubMed (PMID: 38737349) – a randomized controlled clinical trial evaluating the safety and efficacy of transcranial photobiomodulation in children with autism.

Note: Consult a specialist doctor or the child's therapist before starting any therapy.